1. In Vivo
  2. >>Archive

Early Movers in RNAi

Novartis AG has led a handful of Big Pharma into the potential new therapeutic modality of RNAi. Here we review those early moves in this nascent field, and take a look at which of the industry's big players has got game in RNAi. Sidebar to "Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps"

The first few Big Pharma moves into RNA interference were tentative and tightly circumscribed, low risk target- or therapeutic area-specific alliances built around indications where localized delivery wasn’t insurmountable. The fundamental idea of RNAi—using double-stranded RNA oligonucleotides to silence gene expression via destruction of certain mRNA sequences—was promising if early stage. And serious chemistry hurdles needed to be overcome to deliver the potential therapies to their site of action in the body. Even though just about every pharmaceutical company was probably using RNAi as a laboratory tool to validate drug targets, few were eager to place big bets on its therapeutic utility. Big Pharma, which had barely wrapped its collective mind around investing big in more conventional large molecules, hesitated.

Novartis in September 2005 struck the first broad strategic alliance in the space, with Alnylam Pharmaceuticals Inc. [See Deal]...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.